SCHEDULE: Nextech Entities Divest Cargo Therapeutics Stake

Nextech VII GP S.a. r.l. and affiliated entities report zero beneficial ownership in Cargo Therapeutics, Inc. common stock, indicating a full divestment from their previously reported stake.

Summary

• Nextech VII GP S.a. r.l., Nextech VII Oncology SCSp, Ian Charoub, Costas Constantinides, and Rocco Sgobbo (collectively, the "Reporting Persons") have filed an Amendment No. 1 to their Schedule 13G.
• The Reporting Persons collectively report 0.00 shares of Cargo Therapeutics, Inc. common stock beneficially owned as of September 30, 2025.
• This represents 0.0% of the class of Cargo Therapeutics, Inc. common stock.
• The filing indicates a complete divestment of their previously reported beneficial ownership in the company.
• The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.

Sentiment

Score: 5

Explanation: The filing is a factual report of a change in beneficial ownership, specifically a complete divestment. It does not contain information that would inherently be positive or negative for the company's operational performance, thus a neutral sentiment score is appropriate.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Cargo Therapeutics, Inc.'s future performance or operations.

Industry Context

This filing reflects a change in institutional investment in the biotechnology and pharmaceutical sector, specifically within oncology therapeutics. The complete divestment by Nextech entities, which are associated with venture capital and private equity, suggests a strategic portfolio adjustment or a conclusion of their investment thesis in Cargo Therapeutics, Inc. This type of ownership change is common in the dynamic biotech industry where investment cycles can be relatively short, driven by clinical trial milestones, regulatory approvals, or M&A activities.

Stakeholder Impact

• Shareholders of Cargo Therapeutics, Inc. may view the complete divestment by Nextech entities as a signal regarding the investment attractiveness or future prospects of the company, potentially influencing market sentiment.
• Potential investors might consider this divestment as part of their due diligence when evaluating Cargo Therapeutics, Inc.

Key Dates

Keywords

Cargo Therapeutics, Nextech, Schedule 13G, beneficial ownership, divestment, common stock, institutional investor